Ignite Creation Date:
2024-05-05 @ 11:28 AM
Last Modification Date:
2024-10-26 @ 9:08 AM
Study NCT ID:
NCT00057343
Status:
TERMINATED
Last Update Posted:
2006-09-12
First Post:
2003-03-31
Brief Title:
Safety and Efficacy of Zevalin in the Treatment of Non-Hodgkins Lymphoma
Sponsor:
Biogen
Organization:
Biogen
Study Overview
Official Title:
A Prospectively Randomized Phase III Multicenter Controlled Trial to Evaluate the Safety and Efficacy of the Zevalin Therapeutic Regimen Plus Rituxan Compared With Rituxan Alone in Patients With Relapsed or Refractory Follicular NHL
Status:
TERMINATED
Status Verified Date:
2006-09
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
No
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The purpose of this study is to provide treatment for patients who have relapsed NHL or refractory NHL and to determine the effectiveness and safety of the Zevalin and Rituxan regimens or Rituxan therapy alone on your disease
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None